Citeline’s Post

📰 Mind your Ps and Ps: What’s New in Rx Policy. Patients, personalities, and pricing are driving big shifts in prescription oversight. From EU pharma reforms to FDA leadership moves and Medicare hints on GLP-1s. 👉 This week’s Pink Sheet has it all. Read and subscribe today!

To view or add a comment, sign in

Explore content categories